Skip to main content
Jozefina Casuscelli on Muck Rack

Jozefina Casuscelli

As seen in: European Urology, UroToday
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jozefina

Contact Jozefina, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS).

|
By Stefanie Zschäbitz, Irfan Bhatti, Jozefina Casuscelli
| UroToday Verified
Enfortumab vedotin plus pembrolizumab (EVP) is the standard first-line treatment for metastatic or locally advanced urothelial carcinoma (m/laUC). Real-world patients frequently present with unfavorable clinical characteristics, raising uncertainty about whether outcomes mirror those of the pivotal EV-302/KEYNOTE-A39 trial. This study assessed effectiveness and safety of EVP in a real-world cohort of patients with m/laUC.
Open in Who Shared Issue with article?

Aberrant Splice Variants: A Novel Characterization of Clear Cell Renal Cell Carcinoma

|
By Jozefina Casuscelli, Ludwig Maximilian, Sumanta K. Pal
| European Urology Verified
Most eukaryotic genes are expressed on removal of introns from mRNA precursors via a process termed pre-mRNA alternative splicing (AS). This step allows regulated generation of multiple mRNA and protein products from a single gene. AS modifies more than 90% of human genes to generate different transcripts, often encoding proteins with divergent functions []. This precisely regulated process is responsible for proteomic diversity in humans and contributes to physiological functions.
Open in Who Shared Issue with article?

Are We Ready for Adjuvant Sunitinib in High-risk Renal Cell Carcinoma?

|
By Jozefina Casuscelli, Ludwig-Maximilians, James J. Hsieh
| European Urology Verified
Renal cell carcinoma (RCC), which is predominantly of clear cell renal histology (ccRCC), is among the most lethal of urologic malignancies.
Open in Who Shared Issue with article?
See all 5 articles